Contaminants,
such as microparticles, found in the manufacturing stream of
biopharmaceuticals
must be identified and the source determined in order to take
corrective
actions. Biopharmaceuticals differ
significantly from conventional pharmaceutics in the manufacturing and
delivery. They are produced by molecular
cloning and
cell culture fermentation, purified by multiple HPLC runs, and
formulated as
injectables to bypass the digestive system.
Each step in the process presents different contamination risks. Contaminant incidents can lead to production
slow down, quarantine of material and even product loss.
For final products delivered in liquid
formulation any visible contamination is unacceptable.
Our laboratory employs multiple micro-spectroscopic
techniques to investigate and identify unknown materials that are
involved in
contaminant incidents. The techniques
include, but are not limited to, optical microscopy, FTIR-microscopy,
and
scanning electron microscopy (
Gianpiero
“Gianni” Torraca is currently a Sr. Scientist
in the Amgen Forensic
Analysis Group working on identification of extraneous matter and
advantageous
materials in the biopharmaceutical environment as well as surface
characterization. He has worked at
Amgen for 7 years and previously was at Schering Plough Research
Institute for
10 years. Education includes MS
Chemistry from